Label-free Redox Imaging of Patient-Derived Organoids Using Selective Plane 
Illumination Microscopy.

Favreau, Peter F.; He, Jiaye; Gil, Daniel A.; Deming, Dustin A.; Huisken, Jan; Skala, Melissa C.

doi:10.1364/BOE.389164

Datensatz

DATENSATZ AKTIONENEXPORT

Zur Ablage hinzufügen

Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben

Zeitschriftenartikel

Label-free Redox Imaging of Patient-Derived Organoids Using Selective Plane Illumination Microscopy.

MPG-Autoren

/persons/resource/persons219232

He, Jiaye
Max Planck Institute for Molecular Cell Biology and Genetics, Max Planck Society;

/persons/resource/persons219250

Huisken, Jan
Max Planck Institute for Molecular Cell Biology and Genetics, Max Planck Society;

Externe Ressourcen

Es sind keine externen Ressourcen hinterlegt

Volltexte (beschränkter Zugriff)

Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.

Volltexte (frei zugänglich)

Es sind keine frei zugänglichen Volltexte in PuRe verfügbar

Ergänzendes Material (frei zugänglich)

Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar

Zitation

Favreau, P. F., He, J., Gil, D. A., Deming, D. A., Huisken, J., & Skala, M. C. (2020). Label-free Redox Imaging of Patient-Derived Organoids Using Selective Plane Illumination Microscopy. Biomedical Optics Express, 11(5), 2591-2606. doi:10.1364/BOE.389164.

Zitierlink: https://hdl.handle.net/21.11116/0000-0008-A2DC-9

Zusammenfassung

High-throughput drug screening of patient-derived organoids offers an attractive platform to determine cancer treatment efficacy. Here, selective plane illumination microscopy (SPIM) was used to determine treatment response in organoids with endogenous fluorescence from the metabolic coenzymes NAD(P)H and FAD. Rapid 3-D autofluorescence imaging of colorectal cancer organoids was achieved. A quantitative image analysis approach was developed to segment each organoid and quantify changes in endogenous fluorescence caused by treatment. Quantitative analysis of SPIM volumes confirmed the sensitivity of patient-derived organoids to standard therapies. This proof-of-principle study demonstrates that SPIM is a powerful tool for high-throughput screening of organoid treatment response.